<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557619</url>
  </required_header>
  <id_info>
    <org_study_id>M16-185</org_study_id>
    <nct_id>NCT03557619</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies</brief_title>
  <official_title>A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of
      ethinyl estradiol and levonorgestrel in female participants with different hematological
      malignancies. Upon completion of this study, participants receiving clinical benefit in the
      opinion of the investigator and without any clinically significant evidence of disease
      progression with no access to venetoclax (not approved for the treated indication) may
      continue receiving venetoclax at the discretion of the investigator in a separate extension
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">June 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax of Venetoclax</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of Venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of (ethinyl estradiol) EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of EE/Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Venetoclax</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of EE/Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of Venetoclax</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of Venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of EE/Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of Venetoclax</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt) of Venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt) of EE/Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of EE/Levonorgestrel</measure>
    <time_frame>Up to approximately 59 days after initial study drug dose</time_frame>
    <description>AUC from time 0 extrapolated to infinite time (AUCinf) of EE/Levonorgestrel.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Ethinyl estradiol/Levonorgestrel and Venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethinyl estradiol/levonorgestrel is administered on Period 1 Day 1 and then again on Period 3 Day 1. Venetoclax is administered on Period 2 Day 1 and then daily thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet; oral</description>
    <arm_group_label>Ethinyl estradiol/Levonorgestrel and Venetoclax</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol/levonorgestrel</intervention_name>
    <description>tablet; oral</description>
    <arm_group_label>Ethinyl estradiol/Levonorgestrel and Venetoclax</arm_group_label>
    <other_name>Levora</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have relapsed or refractory non-Hodgkin's lymphoma (NHL).

          -  Participant must have histologically documented diagnosis of one of the following NHL
             subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL),
             lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), marginal zone lymphoma
             (MZL), T-cell prolymphocytic lymphoma (T-PLL), Waldenstr√∂m's macroglobulinemia (WM)

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or
             equal to two.

          -  Must have adequate bone marrow, coagulation, renal and hepatic function as described
             in the protocol.

          -  A female of non-childbearing potential as described in the protocol.

        Exclusion Criteria:

          -  History of currently active, clinically significant cardiovascular disease.

          -  If the participant has had prior stem cell transplantation, it must have been more
             than 100 days prior to start of study drug, with no graft versus host disease, and no
             immunosuppression therapy.

          -  evidence of transformation of the lymphoma immediately prior to study entry.

          -  Evidence of central nervous system involvement by lymphoma.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 209090</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Med Ctr /ID# 169097</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research /ID# 207039</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com</url>
    <description>Related info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Hematologic Malignancies, venetoclax</keyword>
  <keyword>ethinyl estradiol</keyword>
  <keyword>relapsed or refractory non-Hodgkin's lymphoma</keyword>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

